title: A new era in the management of psoriasis? The biologics: facts and controversies.
abstract: During the last 30 years, the tremendous progress in our knowledge of the pathogenesis of psoriasis has led to the development of new agents, the so-called biologics, that have revolutionized the management of severe psoriasis. Dermatologists and patients see this emerging therapy as a new perspective in the state of the art in managing moderate to severe psoriasis. After a few years of use in daily practice, we may begin to analyze the power of the currently available biologic agents in the management of severe psoriasis from the perspective of facts.
authors.affiliation: Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, 08916-Badalona, Spain. cferrandiz.germanstrias@gencat.cat
authors.forename: Carlos
authors.initials: C
authors.lastname: Ferrándiz
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: Carrascosa
authors.forename: Aram
authors.initials: A
authors.lastname: Boada
mesh_terms: D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003879:Dermatologic Agents / Q000191:economics* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy / Q000191:economics* / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014466:Ultraviolet Rays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000069285:Infliximab; D000077944:Alefacept; D000068800:Etanercept; C472181:efalizumab